GAU 1636

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

IIOO NEW YORK AVENUE, N.W., SUITE 600 WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE
MICHAEL O. LEE
STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.

DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
NOEL B. WHITLEY
JEFFREY T. HELVEY*
HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
BRIAN S. ROSENBLOOM

LAWRENCE B. BUGAISKY CRYSTAL D. SAYLES* EDWARD W. YEE ALBERT L. FERRO* DONALD R. BANOWIT* PETER A. JACKMAN* MOLLY A. MCCALL* TERESA U. MEDLER* JEFFREY S. WEAVER* DONALD J. FEATHERSTONE**
KAREN R. MARKOWICZ**
GRANT E. REED**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
CAMERON H. TOUS!**
VINCENT L. CAPUANO**

ROBERT H. BENSON*
OF COUNSEL

*BAR OTHER THAN D.C.

**REGISTERED PATENT AGENTS



April 27, 1999

WRITER'S DIRECT NUMBER: (202) 789-5525
INTERNET ADDRESS: BRIAND@SKGF.COM

Assistant Commissioner for Patents Washington, D.C. 20231

APR 2 8 1999

Re: U.S. Utility Patent Application

Appl. No. 09/177,387; Filed: October 23, 1998

For: Recombinational Cloning Using Nucleic Acids Having Recombination

Sites

Inventors: HARTLEY et al.

Our Ref: 0942.2850004/RWE/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement (in duplicate);
- 2. Form PTO-1449 (2 pages);
- 3. Two cited references; and
- 4. One return post card

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Assistant Commissioner for Patents April 27, 1999 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Agent for Applicants Registration No. 42,473

RWE/BJD/dmb Enclosures

P:\USERS\DBARNES\BRIAN\0942\285-4\ids.trans SKGF Rev. 9/23/98 dcw

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARTLEY et al.

Appl. No.: 09/177,387

Filed: October 23, 1998

For: Recombinational Cloning Using

Nucleic Acids Having Recombination Sites Art Unit: 1636

Examiner: Yucel, R.

Auy Docket: 0942.2850004/RWE/BJD

APR 27 1999

First Supplemental Information Disclosure Statement

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants in compliance with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of the documents is also included herewith.

The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed **April 15**, 1999, in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not

HARTLEY et al. Appl. No.: 09/177,387

exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This First Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is attached.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Brian J. Del Buono Agent for Applicants Registration No. 42,473

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005

(202) 371-2600